Compounded vs. Branded
GLP-1 Savings Calculator

The price difference between branded and compounded GLP-1 medications can be staggering — over $12,000 per year in some cases. This calculator shows your exact savings, the tradeoffs, and the cheapest FDA-approved alternative.

Compounded vs. Branded Savings Calculator

See your monthly and annual savings — and all the tradeoffs

Total cost over treatment period
Compounded vs. branded tradeoffs
Pricing as of April 2026: Wegovy list $1,349/mo · Zepbound list $1,059/mo · Zepbound LillyDirect vials $349/mo · Compounded sema $99–$350/mo · Compounded tirz $250–$500/mo. Compounded semaglutide availability is legally restricted in many states following the FDA's 2025 shortage resolution. Always verify current pricing and availability directly with providers. These figures are estimates only.

The price gap — and why it exists

Branded GLP-1 medications are among the most expensive drugs in the world. Wegovy costs approximately $1,349/month and Zepbound $1,059/month at list price — driven by the enormous R&D investment behind them and the absence of generic competition. Novo Nordisk and Eli Lilly hold patents that prevent generic versions from entering the market until the mid-2030s at the earliest.

Compounding pharmacies can legally prepare copies of medications under specific circumstances — primarily when a drug is on the FDA shortage list. When semaglutide was declared in shortage (2022–2025), this opened a large window for compounded versions at dramatically lower prices. The FDA resolving the semaglutide shortage in early 2025 has largely closed that window for semaglutide, but tirzepatide compounding remains more broadly available.

Important 2025–2026 update: The FDA declared the semaglutide shortage resolved in early 2025. This legally restricts most compounding pharmacies from producing semaglutide copies. Many telehealth platforms pivoted to FDA-approved Wegovy or to tirzepatide compounding. If you're seeking compounded semaglutide in 2026, verify availability in your state — it varies significantly and is actively changing.

All your options compared

OptionMonthly costFDA approvedAvailable
Wegovy (branded sema)$1,349Yes ✓Yes
Wegovy + savings card (commercial ins.)$0–225Yes ✓Yes — if insured
Zepbound (branded tirz)$1,059Yes ✓Yes
Zepbound LillyDirect vials$349Yes ✓Yes — self-pay
Compounded semaglutide$99–350No ✗Restricted in most states
Compounded tirzepatide$250–500No ✗More broadly available

Is compounded medication as effective?

Compounded semaglutide and tirzepatide contain the same active ingredient as their branded counterparts — but quality, concentration, and purity can vary significantly between compounding pharmacies. Key differences:

  • No FDA manufacturing oversight: Branded drugs undergo rigorous FDA facility inspections; compounding pharmacies have less oversight
  • No clinical trial data: Branded drugs have multi-year Phase 3 efficacy and safety data; compounded versions do not
  • Salt form differences: Some compounded products use semaglutide sodium or acetate salts rather than the base form used in Wegovy — these may have different absorption profiles
  • Reconstitution required: Many compounded versions come as powder or concentrated solution requiring proper preparation

Bottom line: For many patients, compounded GLP-1 medications from reputable 503B pharmacies have worked well. But the lack of FDA oversight means quality varies, and availability is now legally restricted for semaglutide. If cost is the driving factor, Zepbound vials via LillyDirect ($349/month) offer an FDA-approved middle ground.

Frequently asked questions

Compounded semaglutide typically costs $99–$350/month compared to Wegovy's list price of $1,349/month — a potential saving of $1,000–$1,250/month or $12,000–$15,000/year. However, compounded semaglutide availability has been restricted since the FDA resolved the shortage in early 2025. Many platforms have shifted to compounded tirzepatide instead, which remains more broadly available.
Yes — compounded tirzepatide remains more broadly available than compounded semaglutide in 2026, as the FDA has not resolved the tirzepatide shortage in the same way. Telehealth platforms typically offer compounded tirzepatide for $250–$500/month. Availability varies by state, so verify with providers in your location.
Lilly Direct's Zepbound vials program offers tirzepatide at $349/month for self-pay patients — the cheapest FDA-approved option available nationwide. This uses the same active ingredient as Zepbound auto-injectors but in vial form requiring a separate syringe for administration. The vials are ordered through Lilly's direct portal and require a valid prescription.
Compounded medications carry higher risk than FDA-approved branded drugs because they lack standardized manufacturing oversight. Risks include variable potency and purity, incorrect dosing due to reconstitution errors, and the use of different salt forms that may behave differently in the body. Using a reputable 503B outsourcing facility (which has more oversight than standard compounding pharmacies) reduces but doesn't eliminate these risks.